J Neurogastroenterol Motil.
2010 Jan;16(1):61-70.
The Effect of Tegaserod on Symptoms and Quality of Life in Korean Women with Irritable Bowel Syndrome with Constipation
- Affiliations
-
- 1Wonkwang University College of Medicine, Iksan, Jeollabuk-do, Korea. medcsc@wmc.wonkwang.ac.kr
- 2Catholic University College of Medicine, Seoul, Korea.
- 3Chung-Ang University College of Medicine, Seoul, Korea.
- 4Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea.
- 5Sungkyunkwan University College of Medicine, Seoul, Korea.
- 6Konkuk University College of Medicine, Seoul, Korea.
- 7Soonchunhyang University College of Medicine, Seoul, Korea.
- 8Ewha Womans University College of Medicine, Seoul, Korea.
- 9Ajou University College of Medicine, Suwon, Gyeonggi-do, Korea.
Abstract
-
INTRODUCTION: Tegaserod has been used for treatment of irritable bowel syndrome (IBS) but there is no data regarding its effect on Korean patients. The aim of this study was to evaluate the effect of tegaserod on symptoms and quality of life (QOL) in Korean female IBS patients with constipation and to evaluate the usefulness of the IBS-QOL in clinical study.
METHODS
A prospective, open labeled, multicenter study was performed. Female patients fulfilling Rome II criteria for IBS received 6 mg of tegaserod twice a day for 4 weeks. The efficacy on IBS symptoms and QOL was assessed using 7-point scaled symptom questionnaire and IBS-QOL questionnaire, respectively.
RESULTS
A total of 81 female patients (range 18-73 years of age) were enrolled in this study. Tegaserod therapy significantly reduced the overall symptom scores after 4 weeks (p <0.01). The improved symptoms included abdominal discomfort or pain, hard or lumpy stool, straining during a bowel movement, feeling of incomplete bowel movement, and abdominal fullness or bloating. The IBS-QOL of responders to tegaserod treatment was also significantly improved after 4 weeks (p <0.01). Furthermore, improvement of symptom scores significantly correlated with improvement of the IBS-QOL scores (r = -0.60, p <0.001).
CONCLUSIONS
Tegaserod 6 mg given twice daily improved the QOL as well as the bowel symptoms in Korean female IBS patients with constipation. The IBS-QOL can be used as a reliable end-point in clinical study.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
- Management of Irritable Bowel Syndrome
- Frequency of Irritable Bowel Syndrome, Entrance Examination Stress, Mental Health, and Quality of Life among Adolescent Women
- Comments on Tegaserod Trial on Irritable Bowel Syndrome
- Overlap Syndrome of Functional Dyspepsia and Irritable Bowel Syndrome - Are Both Diseases Mutually Exclusive?
